Abstract | OBJECTIVES:
Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities. We have investigated the common and rare side-effects, especially analysing peripheral neuropathy, in order to optimise the thalidomide dose for minimizing this harmful side-effect. METHODS: Fifty-nine patients were treated with thalidomide alone or combined with oral melphalan. The median age was 69 yr. The initial dose of thalidomide was 100 mg/day increasing weekly by 100 mg increments until a maximum dose of 400 mg was attained. Melphalan was administered at a dose of 0.20 mg/kg/d for 4 d every 28 d. RESULTS AND CONCLUSIONS:
|
Authors | Massimo Offidani, Laura Corvatta, Monica Marconi, Lara Malerba, Anna Mele, Attilio Olivieri, Marino Brunori, Massimo Catarini, Marco Candela, Debora Capelli, Mauro Montanari, Serena Rupoli, Pietro Leoni |
Journal | European journal of haematology
(Eur J Haematol)
Vol. 72
Issue 6
Pg. 403-9
(Jun 2004)
ISSN: 0902-4441 [Print] England |
PMID | 15128418
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
|
Topics |
- Aged
- Aged, 80 and over
- Constipation
(chemically induced)
- Disorders of Excessive Somnolence
(chemically induced)
- Dose-Response Relationship, Drug
- Fatigue
(chemically induced)
- Female
- Humans
- Male
- Melphalan
(administration & dosage)
- Middle Aged
- Multiple Myeloma
(complications, drug therapy)
- Peripheral Nervous System Diseases
(chemically induced, prevention & control)
- Probability
- Thalidomide
(administration & dosage, toxicity)
- Venous Thrombosis
(chemically induced)
|